# Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

> **NCT04811027** · PHASE2 · COMPLETED · sponsor: **Immutep S.A.S.** · enrollment: 171 (actual)

## Conditions studied

- HNSCC

## Interventions

- **DRUG:** eftilagimod alpha
- **DRUG:** pembrolizumab (KEYTRUDA®)

## Key facts

- **NCT ID:** NCT04811027
- **Lead sponsor:** Immutep S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-27
- **Primary completion:** 2024-03-11
- **Final completion:** 2025-11-05
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2025-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04811027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04811027, "Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04811027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*